Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14687576 | 1.00 | TSHR (0.34) | TSHRHTTMMP2MMP9TDP2 | |
| SCHEMBL18132317 | 0.76 | TSHR (0.32) | TSHR | |
| SCHEMBL11616770 | 0.76 | TSHR (0.33) | TSHRHTTMMP2MMP9 | |
| SCHEMBL10827106 | 0.70 | PYGM (0.34) | TSHR | |
| SCHEMBL21030508 | 0.70 | LMNA (0.41) | TSHRHTTLMNA | |
| SCHEMBL14874449 | 0.67 | — | — | |
| SCHEMBL11616499 | 0.67 | — | — | |
| SCHEMBL23462596 | 0.65 | — | — | |
| SCHEMBL11243781 | 0.65 | TP53 (0.37) | TSHRKMT2A | |
| SCHEMBL11239122 | 0.64 | HTT (0.30) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630851-B2 | Polynucleotide modification methods | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-05-19 | — | — | US | claimed |
| US-20260098287-A1 | METHOD AND KIT FOR REGENERATING REUSABLE INITIATORS FOR NUCLEIC ACID SYNTHESIS | CHENG-YAO CHEN (TW) | 2026-04-09 | — | — | US | claimed |
| US-12577615-B2 | Methods for the detection of a nucleic acid | RHODX, INC. (US) | 2026-03-17 | — | — | US | claimed |
| WO-2025245282-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF PROTEIN ANALYTES | RANGE BIOTECHNOLOGIES, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| US-20250340935-A1 | METHODS FOR THE DETECTION OF A NUCLEIC ACID | RHODX INC (US) | 2025-11-06 | — | — | US | claimed |
| EP-4569132-A2 | METHOD, KIT AND SYSTEM FOR END LABELING OF NUCLEIC ACIDS | Chen, Cheng-Yao (TW) | 2025-06-18 | — | — | EP | claimed |
| WO-2025021984-A1 | METHOD FOR GENERATING A PLURALITY OF POLYNUCLEOTIDES | DNA SCRIPT (FR) | 2025-01-30 | — | — | WO | claimed |
| US-20250019744-A1 | METHOD, KIT AND SYSTEM FOR END LABELING OF NUCLEIC ACIDS | Chen, Cheng-Yao (TW) | 2025-01-16 | — | — | US | claimed |
| US-12084715-B1 | Methods and systems for reducing artifactual antisense products | 10X GENOMICS, INC. (US) | 2024-09-10 | — | — | US | claimed |
| WO-2024138550-A1 | NUCLEIC ACID AMPLIFICATION METHOD AND USE THEREOF IN SEQUENCING | 深圳华大智造科技股份有限公司 | 2024-07-04 | — | — | WO | claimed |
| WO-2001051669-A9 | NUCLEIC ACID BINDING ASSAY AND SELECTION METHOD | GENELABS TECH INC (US) | 2001-11-29 | — | — | WO | claimed |
| WO-2001051669-A2 | NUCLEIC ACID BINDING ASSAY AND SELECTION METHOD | GENELABS TECHNOLOGIES, INC. (US) | 2001-07-19 | — | — | WO | claimed |
| US-5919472-A | DETOXIFYING ALDEHYDE-FIXED BIOLOGICAL TISSUE, SUCH AS HEART VALVE FOR IMPLANTATION BY USING A CYCLIC NONPEPTIDYL AMIDE AND/OR IMIDE FUNCTIONAL COMPOUND SUCH AS ALLANTOIN TO REMOVE EXCESS ALDEHYDE FROM THE TISSUE | MEDTRONIC, INC. (US) | 1999-07-06 | — | — | US | claimed |
| US-5906918-A | QUANTITATING BASE MODIFICATIONS IN SAMPLE DNA BY ENDONUCLEASE DIGESTION TO DINUCLEOSIDE MONOPHOSPHATES, DEPHOSPHORYLATION, LABELING SAMPLE AND INTERNAL STANDARD DNA, ADDING COMIGRATING CARRIERS, SEPARATING SAMPLE/CARRIER FROM STANDARD/CARRIER | HEALTH RESEARCH INC. (US) | 1999-05-25 | — | — | US | claimed |
| US-5871992-A | REPAIR OF DNA WITH ENZYME OF GLYCOSYLASE/AP LYASE ALSO FUSION PROTEINS | NEW YORK UNIVERSITY (US) | 1999-02-16 | — | — | US | claimed |
| US-5763180-A | In vitro assay for carcinogens using phenotypic transformation of human cells | VIRATEST CARCINOGEN MONITORING LTD. (CA) | 1998-06-09 | — | — | US | claimed |
| EP-0796627-A2 | Treatment of aldehyde-fixed tissue | MEDTRONIC, INC. (US) | 1997-09-24 | — | — | EP | claimed |
| WO-1997031612-A2 | MAMMALIAN ENDONUCLEASE III, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NEW YORK UNIVERSITY (US) | 1997-09-04 | — | — | WO | claimed |
| US-5552285-A | DIAGNOSIS AND MONITORING OF INFLAMMATORY AND AUTOIMMUNE DISEASES | NEW YORK UNIVERSITY (US) | 1996-09-03 | — | — | US | claimed |
| WO-1992015707-A1 | IMMUNOASSAY FOR ANTIBODIES TO OXIDIZED DNA AND USES THEREOF | NEW YORK UNIVERSITY (US) | 1992-09-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577615-B2 | Methods for the detection of a nucleic acid | POLRMT, RNGTT, RNASE1 | TSHR 2066/4885HTT 2632/4885MMP2 685/4885 |
| US-12630851-B2 | Polynucleotide modification methods | PNP, NT5C3B, UNG | TSHR 2677/4885HTT 2017/4885MMP2 2284/4885 |
| US-20260098287-A1 | METHOD AND KIT FOR REGENERATING REUSABLE INITIATORS FOR NUCLEIC ACID SYNTHESIS | DNMT3L, ADAR, UNG | TSHR 3851/4885HTT 4448/4885MMP2 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.